Insider trade

CFO sold ~$159K of UTHR shares in the open market

Traded Apr 23, 2026 · Filed Apr 25, 2026

Why it stands out

The CFO of United Therapeutics sold $159K of United Therapeutics shares. The filing says it was made under a pre-arranged trading plan.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

CFO$100K–$500KPre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$159,495

Shares × reported transaction price

Timing vs results

57 days after results of Feb 25, 2026, 13 days before results of May 6, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	+2.5%	+0.4%	+2.1%
30 days	+0.7%	+4.9%	−4.3%
90 days	−6.9%	+3.3%	−10.2%

Past results only. Not a forecast.

This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025.
This transaction was executed in multiple trades at prices ranging from $569.19 to $570.17. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Filed 5mo ago

Traded May 21 · filed 2 days later

Derivative exercise or conversion — not an open-market buy.

Scheduled in advanceFiled 5mo ago

Scheduled in advanceFiled 5mo ago